X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3711) 3711
Publication (309) 309
Book Review (66) 66
Newsletter (29) 29
Book Chapter (20) 20
Book / eBook (7) 7
Conference Proceeding (6) 6
Magazine Article (4) 4
Dissertation (2) 2
Transcript (2) 2
Data Set (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2879) 2879
index medicus (2223) 2223
male (1639) 1639
female (1508) 1508
cardiac & cardiovascular systems (1324) 1324
heart failure (1242) 1242
middle aged (1152) 1152
natriuretic peptides (1105) 1105
aged (1066) 1066
brain natriuretic peptide (860) 860
natriuretic peptide, brain - blood (781) 781
mortality (738) 738
heart failure - drug therapy (636) 636
animals (616) 616
natriuretic peptide (604) 604
adult (592) 592
biomarkers - blood (588) 588
treatment outcome (588) 588
prognosis (546) 546
risk factors (542) 542
care and treatment (491) 491
heart failure - physiopathology (489) 489
heart (469) 469
hypertension (461) 461
cardiology (448) 448
cardiac patients (432) 432
cardiovascular (420) 420
pharmacology & pharmacy (413) 413
heart-failure (390) 390
analysis (377) 377
peptide fragments - blood (365) 365
biomarkers (359) 359
prospective studies (358) 358
atrial-natriuretic-peptide (347) 347
medicine & public health (340) 340
diagnosis (339) 339
abridged index medicus (336) 336
echocardiography (319) 319
research (301) 301
health aspects (300) 300
aged, 80 and over (298) 298
peptides (297) 297
time factors (295) 295
drug therapy (290) 290
heart failure - blood (290) 290
heart failure - diagnosis (285) 285
heart attacks (279) 279
cardiovascular disease (275) 275
heart diseases (270) 270
follow-up studies (251) 251
internal medicine (250) 250
rats (245) 245
blood pressure (242) 242
risk (240) 240
left-ventricular dysfunction (239) 239
myocardial-infarction (234) 234
double-blind method (226) 226
risk assessment (225) 225
acute disease (224) 224
disease (223) 223
acute myocardial-infarction (222) 222
medicine, general & internal (222) 222
medical research (216) 216
predictive value of tests (216) 216
therapy (214) 214
patients (212) 212
congestive-heart-failure (209) 209
heart failure - mortality (207) 207
double-blind (203) 203
peripheral vascular disease (203) 203
heart failure - therapy (197) 197
atrial natriuretic factor - blood (196) 196
blood pressure - drug effects (195) 195
dysfunction (195) 195
studies (191) 191
c-reactive protein (186) 186
rodents (186) 186
medicine, experimental (185) 185
angiotensin (183) 183
natriuretic peptide, brain - therapeutic use (181) 181
clinical trials (179) 179
cardiovascular diseases (177) 177
surgery (177) 177
diabetes (176) 176
outcomes (176) 176
medical colleges (174) 174
article (172) 172
cardiotonic agents - therapeutic use (171) 171
physiological aspects (167) 167
blood-pressure (166) 166
cardiology and cardiovascular medicine (164) 164
chronic disease (163) 163
survival (163) 163
antihypertensive agents - therapeutic use (162) 162
medicine (161) 161
medicine, research & experimental (161) 161
prognostic value (159) 159
respiratory system (159) 159
management (158) 158
natriuretic agents - therapeutic use (158) 158
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3724) 3724
French (10) 10
German (7) 7
Russian (6) 6
Chinese (4) 4
Spanish (4) 4
Italian (3) 3
Japanese (2) 2
Polish (2) 2
Portuguese (2) 2
Arabic (1) 1
Czech (1) 1
Hungarian (1) 1
Norwegian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 08/2017, Volume 377, Issue 7, pp. 644 - 657
In this report of two randomized trials, patients with type 2 diabetes at risk for cardiovascular disease received the sodium–glucose cotransporter 2 inhibitor... 
METAANALYSIS | ATRIAL-NATRIURETIC-PEPTIDE | RATIONALE | INTENSIVE GLUCOSE CONTROL | PLACEBO-CONTROLLED TRIAL | OUTCOMES | INHIBITORS | STAGE KIDNEY-DISEASE | PROGRESSION | BASE-LINE CHARACTERISTICS | MEDICINE, GENERAL & INTERNAL | Hypoglycemic Agents - therapeutic use | Albuminuria - complications | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Kidney Diseases - mortality | Male | Canagliflozin - adverse effects | Disease Progression | Foot - surgery | Glomerular Filtration Rate - drug effects | Diabetes Mellitus, Type 2 - physiopathology | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Female | Aged | Amputation - statistics & numerical data | Kidney Diseases - etiology | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Diabetes Mellitus, Type 2 - complications | Type 2 diabetes | Heart | Complications and side effects | Care and treatment | Abnormalities | Amputation | Myocardial infarction | Heart attacks | Body weight | Clinical trials | Cardiovascular disease | Blood pressure | Drug dosages | Heart failure | Cerebral infarction | Stroke | Statistical analysis | Kidneys | Metatarsal | Diabetes mellitus | Toe | FDA approval | Glomerular filtration rate | Medicine | Studies | Side effects | Sodium | Diabetes | Kidney diseases | Cardiovascular diseases | Health risk assessment | Kidney transplantation
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9982, pp. 2067 - 2076
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2011, Volume 365, Issue 1, pp. 32 - 43
Journal Article
European Heart Journal, ISSN 0195-668X, 04/2017, Volume 38, Issue 15, pp. 1119 - 1127
Journal Article
Cardiovascular Research, ISSN 0008-6363, 05/2017, Volume 113, Issue 6, pp. 564 - 585
Ischaemic heart disease and the heart failure that often results, remain the leading causes of death and disability in Europe and worldwide. As such, in order... 
Ischaemia | Ischaemic conditioning | Myocardial Infarction | Cardioprotection | Reperfusion | Physiology | Cardiology and Cardiovascular Medicine | Physiology (medical) | Journal Article | MICROVASCULAR OBSTRUCTION | CARDIAC & CARDIOVASCULAR SYSTEMS | ATRIAL-NATRIURETIC-PEPTIDE | BYPASS GRAFT-SURGERY | ISCHEMIA-REPERFUSION INJURY | INDUCED VENTRICULAR-FIBRILLATION | PERCUTANEOUS CORONARY INTERVENTION | CYCLOSPORINE-A | ELEVATION MYOCARDIAL-INFARCTION | LONG-TERM BENEFIT | ARTERY-DISEASE | Myocardial Reperfusion Injury - etiology | Ischemic Postconditioning - methods | Humans | Heart Failure - physiopathology | Percutaneous Coronary Intervention - standards | Protective Factors | ST Elevation Myocardial Infarction - therapy | Heart Failure - prevention & control | Ischemic Preconditioning - methods | Myocardial Reperfusion Injury - pathology | Coronary Artery Bypass - standards | Ischemic Preconditioning - adverse effects | Translational Medical Research - methods | Heart Failure - etiology | Cardiology - methods | Disease Models, Animal | ST Elevation Myocardial Infarction - complications | Risk Factors | Treatment Outcome | Cardiology - standards | Heart Failure - pathology | Myocardial Reperfusion Injury - physiopathology | Cardiovascular Agents - therapeutic use | Coronary Artery Bypass - adverse effects | ST Elevation Myocardial Infarction - physiopathology | Animals | Ischemic Preconditioning - standards | Translational Medical Research - standards | Ischemic Preconditioning, Myocardial - methods | Cardiovascular Agents - adverse effects | Percutaneous Coronary Intervention - adverse effects | Myocardial Reperfusion Injury - prevention & control | ST Elevation Myocardial Infarction - pathology | Life Sciences
Journal Article